CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
诱导性 CAR 巨噬细胞作为癌症免疫细胞治疗的新型治疗细胞类型
英文原题：Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies.
查看英文原题
Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法已在血液系统恶性肿瘤治疗中取得进展，但用于实体瘤仍面临多重障碍。表达 CAR 的原代巨噬细胞（CAR-M）以及由诱导多能干细胞（iPSC）衍生的 CAR 表达巨噬细胞（CAR-iMac）已成为有吸引力的替代方案，有望为肿瘤免疫细胞治疗提供高效且低成本的途径。本文综述人源 CAR 巨噬细胞的当前研发状况，并概述其在肿瘤免疫细胞治疗领域的关键功能。
展开英文摘要原文
The Chimeric antigen receptor (CAR)-T cell therapy has made inroads in treating hematological malignancies. Nonetheless, there are still multiple hurdles in CAR-T cell therapy for solid tumors. Primary CAR-expressing macrophage cells (CAR-Ms) and induced pluripotent stem cells (iPSCs)-derived CAR-expressing macrophage cells (CAR-iMacs) have emerged as attractive alternatives in our quest for an efficient and inexpensive approach for tumor immune cell therapy.
In this review, we list the current state of development of human CAR-macrophages and provide an overview of the crucial functions of human CAR-macrophages in the field of tumor immune cell therapy.
论文信息
- 作者
- Su S、Lei A、Wang X、Lu H、Wang S、Yang Y、Li N、Zhang Y
- 第一作者单位
- Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, China.China
- 通讯作者单位
- Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou 311121, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cells2022 May 16
- 原文标识
- PubMed 35626689 · DOI 10.3390/cells11101652
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →